Should you buy Pfizer stock now?
Yes, the technical signal for Pfizer is currently Strong Buy. Pfizer trades at $27.48 as of Oct 7, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 0.108 with falling momentum (signal: 0.242); RSI is at 43.8 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $28.88 points to 5.1% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Pfizer stock?
The average analyst price target for Pfizer is $28.88. The current price is $27.48, which gives an upside of 5.1%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $25.99 and $31.77.
Is Pfizer a dividend stock?
Yes, Pfizer is a dividend stock with a dividend yield of 5.99%. The latest dividend was $0.43 per share. The latest ex-dividend date (traded without the dividend) was Jul 24, 2026. The payout ratio is 56.4%, which is considered moderate.
When does Pfizer pay a dividend in 2026?
The next dividend date for Pfizer has not been set yet. The latest ex-dividend date (last trading day with dividend rights) was Jul 24, 2026. The latest dividend was $0.43 per share with an ex-dividend date of Jul 24, 2026. The dividend yield is 5.99%. The payout ratio of 56.4% points to moderate dividend coverage.
What is the risk of Pfizer stock?
Pfizer is rated as a stock in the risk category Conservative. the annual standard deviation is 21.2%, which classifies the stock as Conservative.
Is Pfizer overvalued?
Pfizer is considered fairly valued – the price is close to the analyst price target. Pfizer has the following valuation ratios: a P/E ratio of 37.8 (highly valued), a P/S ratio of 2.6, a P/B ratio of 1.9. The stock trades close to the analyst price target and is considered fairly valued.
Is Pfizer overbought?
No, Pfizer is not overbought. RSI is at 43.8 (neutral zone). The technical indicators show: RSI is at 43.8 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.7% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next Pfizer earnings report?
Pfizer reports its next earnings on November 3, 2026. The stock currently trades at $27.48. With a P/E ratio of 37.8, the market will be watching closely whether earnings meet expectations.
Is Pfizer shorted?
Yes, Pfizer is shorted with 2.7% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Pfizer stock?
Yes, insiders are net buyers of Pfizer – they are buying more shares than they are selling. Over the last 3 months, insiders have made 3 purchases and 1 sales. On a net basis, 2,876,849 $ worth of shares were bought. Across the last 20 reported transactions, the split is 10 purchases and 10 sales, with a net 688,913 $ sold. Active buyers include BOURLA ALBERT, Buckley Mortimer J, BLAYLOCK RONALD E and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Pfizer a good stock?
Based on our total score, Pfizer is rated as a good stock with a total score of 66 out of 100. The stock scores above average on value, quality and momentum. The score is made up of Value: 47/100, Quality: 73/100, Momentum: 78/100. In addition: a dividend of 5.99%; technical signal: Strong Buy. Whether Pfizer is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Pfizer stock?
The outlook for Pfizer based on current data: the average analyst price target is $28.88 (+5.1%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on Nov 3, 2026, which can move the price; the P/E ratio is 37.8 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Pfizer stock moving?
Pfizer is stable right now. The technical indicators show: the price is close to the 20-day average; insiders have mostly been buying the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Pfizer go?
The average analyst price target for Pfizer is $28.88, which corresponds to a potential gain of 5.1% from the current price of $27.48. The stock has traded between $22.57 and $29.21 over the last 52 weeks. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Pfizer fall?
The stock has traded as low as $22.57 over the last 52 weeks — that is 17.9% below the current price of $27.48. The biggest decline (drawdown) in the same period was 22.7% from high to low. Within a year, the price typically swings about ±21.2% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Pfizer do?
Pfizer makes and sells medicines and vaccines around the world. The company earns money by discovering, developing and selling these products to treat many different illnesses.
Pfizer covers several areas of health. For heart and blood vessel diseases, it makes a treatment ca... The company belongs to the Healthcare sector, more specifically the Drug Manufacturers - General industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Pfizer as an investment.
Did Pfizer raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Pfizer. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Pfizer making money or losing money?
Yes, Pfizer is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 6.8% — which is moderate. The operating margin (profit before interest and taxes) is 27.9%. At a P/E ratio of 37.8, you currently pay 37.8 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Pfizer go bankrupt?
The bankruptcy risk of Pfizer is rated as low. Altman Z2 (a model for assessing financial distress) is 3.11 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 142% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Pfizer have a lot of debt?
Pfizer has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 142%. For the healthcare sector, 80-150% counts as a typical level. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Pfizer service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is 0.0x, and net debt equals 2.5 years of earnings (EBITDA).
